Cefmenoxime concentrations in gallbladder bile and tissue were assessed in patients undergoing cholecystectomy. A 0.5-g intravenous dose produced mean concentrations in bile of 54.1 ,ug/ml at 62.9 min and 56.3 jxg/ml at 194 min after the dose was given. A 1.0-g intravenous dose produced concentrations in bile of 117.9 ,ug/ml at 53 min and 169.7 ,ug/ml of 194 min after the dose was given. Mean concentrations in tissue ranged from 6.1 to 17.9 ,ug/g. Biliary tree penetration was dose and time dependent. Therapeutic concentrations were achieved.
Biliary tree infection is caused primarily by gram-negative enteric bacilli such as Escherichia coli and Klebsiella, Proteus, and Enterobacter spp., and less often by anaerobic bacteria, particularly Clostridium spp. (1, 2, (5) (6) (7) (8) (9) (10) 12) . Cefmenoxime, a comparatively new, broad-spectrum, semisynthetic cephalosporin with activity against many of these bacteria (4, 11, 13) , was evaluated for its ability to penetrate gallbladder bile and tissue at therapeutic concentrations.
Patients admitted to the Hahnemann University Hospital for cholecystectomy were enrolled. Informed consent was obtained from each patient. No patient had evidence of abnormal renal or hepatic function. Penicillin-and cephalosporin-allergic patients were not enrolled. Patients meeting the inclusion criteria received cefmenoxime (Abbott Laboratories, Chicago, Ill.) in a single dose at 0.5 or 1.0 g intravenously over 20 to 30 min, either concurrently with anesthesia or 2 to 4 h preoperatively.
Gallbladder bile was obtained by needle aspiration. Gallbladder tissue was washed with sterile physiological saline and dried with gauze until all contaminating bile and blood was removed. A 1.0-g section of gallbladder tissue was combined with phosphate buffer (pH 8) and homogenized. Serum samples were obtained to determine cefmenoxime levels immediately after drug infusion, at the time gallbladder bile was obtained, and 4 h after the dose was given. All samples were stored at -70°C until assay.
Specimens were assayed by the microbiological agar diffusion technique using Bacillus subtilis ATCC 6633 as the test organism. Standards were prepared in bile and gallbladder wall samples from patients who did not receive perioperative antimicrobial prophylaxis. Concentrations below the limit of the assay were determined by a modified high-pressure liquid chromatographic procedure (3, 7).
Complete blood count with differential, platelet count, serum creatinine, sequential multichannel autoanalyzer-12, serum electrolytes, Coombs test, urinalysis, prothrombin and partial thromboplastin times, and physical examination were performed for each patient before and after the administration of cefmenoxime. An oral cholecystogram or cholescintillography was performed before surgery.
Nineteen patients were enrolled in the study. Four were evaluated for drug concentrations in gallbladder wall and serum only. The mean values for total bilirubin, alkaline phosphatase, serum glutamic oxaloacetic transaminase, and serum creatinine were within normal limits before and after surgery for all patients.
Seven female and two male patients received the 0.5-g dose, and five females and five males received the 1.0-g dose. The average weight of the patients in each group was 69.8 and 75.5 kg, respectively. The mean peak concentration of cefmenoxime in serum was 40.8 (range, 11.0 to 85.0) pug/ml in the 0.5-g group and 53.5 (range, 32.0 to 87.0) pg/ml in the 1.0-g group. Serum levels 4 h after the dose were 3.3 (range, 0.0 to 7.1) pg/ml after the 0.5-g dose and 4.7 (range, 0.0 to 8.0) ,ug/ml after the 1.0-g dose.
Levels of cefmenoxime in gallbladder bile and simultaneously obtained serum levels are shown in Table 1 . Drug levels in gallbladder bile averaged 54.1 (range, 16 to 170) p,g/ml after the 0.5-g dose and 117.9 (range, 1.5 to 204) ,ug/ml after the 1.0-g dose when cefmenoxime was administered at the induction of anesthesia. The time from drug administration to bile sampling averaged 62.9 min after the 0.5-g dose and 48 min after the 1.0-g dose. Drug levels in bile were four-to fivefold greater than those found in serum sampled simultaneously. Drug levels in gallbladder bile averaged 56.3 (range, 0 to 112.5) ,g/ml after the 0.5-g dose and 169.7 (range, 11.8 to 390) ANTIMICROB. AGENTS CHEMOTHER. ,ug/ml after the 1.0-g dose given 2 to 4 h before surgery. The time from drug administration to bile sampling averaged 193.5 min after the 0.5-g dose and 194 min after the 1.0-g dose. Drug levels in bile were 11-to 34-fold greater than those in serum sampled simultaneously. Two patients had cystic duct obstructions detected radiographically before surgery. The respective drug levels in gallbladder bile were 0.0 and 112.5
,ug/ml in these two patients. Five additional patients had nonfunctioning gallbladders and one had a poorly functioning gallbladder, as determined radiologically preoperatively. In five of these six patients, cefmenoxime was detectable in the gallbladder bile in significant concentrations. Drug levels in gallbladder tissue are shown in Table 1 . Cefmenoxime levels in gallbladder tissue were approximately 45% that in serum obtained simultaneously when either the 0.5-or the 1.0-g dose was given at the induction of anesthesia. The time from drug administration to tissue sampling averaged 65 min for the 0.5-g dose and 53 min for the 1.0-g dose. Drug levels in gallbladder tissue were 2.6 times greater than those in serum obtained simultaneously, after the 0.5-g dose and 3.8 times that in serum after the 1.0-g dose given 2 to 4 h preoperatively. The mean time to tissue sampling was 216 min from the time of drug administration.
The results obtained in this study indicate that cefmenoxime penetrates into the biiary tree in high concentrations when given intravenously in doses of 0.5 or 1.0 g. Drug concentrations in bile were dose related. In most cases, cefmenoxime persisted in the bile at high concentrations up to 3.25 h after administration of the dose, although serum levels of the drug were minimal at that time. The concentrations achieved in the bile were manyfold in excess of the minimal inhibitory and minimal bactericidal coticentrations required for Enterobacteriaceae strains commonly involved in biiary tree infection. Concentrations in tissue were also adequate. The data indicate that cefmenoxime may be useful in the treatment of biliary tree infections caused by susceptible organisms.
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